Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Boston Scientific to buy Silk Road Medical in $1.26bn deal

(Sharecast News) - Medical device company Silk Road Medical surged in pre-market trade on Tuesday after saying it had agreed to be bought by Boston Scientific in a $1.26bn deal. Under the terms of the transaction, Silk Road shareholders will receive $27.50 per share in cash.

In a brief statement, Silk Road said its board of directors had unanimously approved the deal and recommend that shareholders adopt the merger agreement.

The transaction is expected to close in the second half of this year.

At 1230 BST, Silk Road shares were up 23% in pre-market trade at $26.70.

Share this article

Related Sharecast Articles

First Property swings to full-year loss
(Sharecast News) - UK and central Europe-focussed property fund manager and investor First Property Group reported a statutory loss before tax of £4.41m in its preliminary results on Wednesday, swinging from a £2.49m profit before tax recorded in the prior year.
Creo Medical reports year of solid progress
(Sharecast News) - Surgical endoscopy medical device specialist Creo Medical Group reported solid progress over the last 12 months in an update on Wednesday, as it leveraged funds from the March 2023 equity raise to advance its strategic goals.
Panthera issues update on Bhukia dispute, secures litigation funding
(Sharecast News) - Gold explorer and developer Panthera Resources updated the market on the ongoing dispute with the Republic of India over the Bhukia project on Wednesday, confirming that it had secured litigation financing for the dispute.
Panthera issues update on Bhukia dispute, secures litigation funding
(Sharecast News) - Gold explorer and developer Panthera Resources updated the market on the ongoing dispute with the Republic of India over the Bhukia project on Wednesday, confirming that it had secured litigation financing for the dispute.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.